comparemela.com

Latest Breaking News On - Announces on schedule completion - Page 1 : comparemela.com

PHARNEXT: Pharnext unveils the latest progress of the PREMIER trial, pivotal Phase III clinical trial of PXT3003 in Charcot-Marie-Tooth disease type 1A

PARIS, France, February 2nd, 2023, 08:30 am CET - Pharnext SA (FR001400BV89 - ALPHA) (the "Company"), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative

United statesFrance generalBaden wübergDeborah schwarzMary jane elliottFabreguettes leibAlexandra harrisonSukaina virjiSchwierige zeitenFinancial press relationsRelations internationalEuronext growth stock exchangeClinical development programConsilium strategic communicationsOverall neuropathy limitations scaleOpen label extension

PHARNEXT: Shareholder Letter: Time to reveal Pharnext true value

PARIS, France, January 11th, 2023, 8:30 am CET - Pharnext SA (FR001400BV89 - ALPHA) (the "Company"), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for rare

United statesFrance generalBaden wübergFabreguettes leibHugo brugiSukaina virjiXavier paoliJames kuoJoshua schaferMary jane elliottRob quinnAlexandra harrisonCompany onEdison investment researchFinancial press relationEuronext growth stock exchange

vimarsana © 2020. All Rights Reserved.